Azitra has initiated a Phase 1b trial for ATR-12 in Netherton syndrome patients, with initial safety data expected in H1 2025 and topline results by year-end 2025.
Azitra dosed the first patient in its Phase 1b trial of ATR-12 for Netherton syndrome, a genetic skin disorder, marking a key milestone in the drug's development.
Azitra dosed the first patient in its Phase 1b trial of ATR-12 for Netherton syndrome, a genetic skin disorder, marking a key milestone in the drug's development.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.